This company has been marked as potentially delisted and may not be actively trading. NASDAQ:BFRA Biofrontera (BFRA) Stock Price, News & Analysis Add Compare Share Share Stock Analysis Stock AnalysisBuy This Stock About Biofrontera Stock (NASDAQ:BFRA) 30 days 90 days 365 days Advanced Chart Get Biofrontera alerts:Sign Up Key Stats Today's Range$2.51▼$2.7850-Day Range$2.50▼$3.6052-Week Range$2.09▼$7.54Volume7,263 shsAverage Volume27,512 shsMarket Capitalization$73.73 millionP/E RatioN/ADividend YieldN/APrice TargetN/AConsensus RatingN/A Company OverviewBiofrontera AG engages in the development, sale and distribution of dermatological drugs and medical cosmetics for the care, protection and treatment of the skin. Its products include Ameluz, BF-RhodolesXepi and Belixos. The company was founded by Hermann Lübbert in 1997 and is headquartered in Leverkusen, Germany.Read More… Receive BFRA Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Biofrontera and its competitors with MarketBeat's FREE daily newsletter. Email Address BFRA Stock News HeadlinesBiofrontera AG’s Q1 2025 Earnings Call HighlightsMay 27 at 8:19 PM | tipranks.comBiofrontera AG Faces Financial Uncertainty Amid Biofrontera Inc. Payment IssuesMay 27 at 2:56 PM | tipranks.comTrump’s treachery Trump’s Final Reset Inside the shocking plot to re-engineer America’s financial system…and why you need to move your money now.May 28, 2025 | Porter & Company (Ad)Biofrontera Inc. (NASDAQ:BFRI) Q1 2025 Earnings Call TranscriptMay 20, 2025 | msn.comQ1 2025 Biofrontera Inc Earnings CallMay 17, 2025 | finance.yahoo.comBiofrontera verlängert Ameluz-Patent für Aknebehandlung bis 2043May 15, 2025 | de.investing.comBiofrontera Inc. droht Delisting von der Nasdaq wegen AktienkursMay 15, 2025 | de.investing.comBiofrontera AG’s Earnings Call Highlights Growth and Strategic AdvancesApril 23, 2025 | tipranks.comSee More Headlines BFRA Stock Analysis - Frequently Asked Questions How were Biofrontera's earnings last quarter? Biofrontera AG (NASDAQ:BFRA) posted its quarterly earnings results on Wednesday, November, 24th. The company reported ($0.24) EPS for the quarter, missing analysts' consensus estimates of ($0.22) by $0.03. The company earned $6.34 million during the quarter. Biofrontera had a negative trailing twelve-month return on equity of 93.31% and a negative net margin of 59.44%. When did Biofrontera IPO? Biofrontera (BFRA) raised $18 million in an IPO on Wednesday, February 14th 2018. The company issued 1,500,000 shares at $11.00-$13.00 per share. Benchmark served as the underwriter for the IPO and Dawson James Securities and Lake Street Capital Markets were co-managers. What other stocks do shareholders of Biofrontera own? Based on aggregate information from My MarketBeat watchlists, some other companies that Biofrontera investors own include AMC Entertainment (AMC), AC Immune (ACIU), Adaptimmune Therapeutics (ADAP), ADMA Biologics (ADMA), Ashford Hospitality Trust (AHT), Akebia Therapeutics (AKBA) and Assembly Biosciences (ASMB). Company Calendar Last Earnings11/24/2021Today5/28/2025Fiscal Year End12/31/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical Preparations Sub-IndustryN/A Current SymbolNASDAQ:BFRA CIK1712641 Webwww.biofrontera.com Phone(921) 487-6320Fax49-02-1487-6320Employees138Year FoundedN/AProfitability EPS (Most Recent Fiscal Year)($0.73) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$14.88 million Net Margins-59.44% Pretax MarginN/A Return on Equity-93.31% Return on Assets-24.02% Debt Debt-to-Equity Ratio0.13 Current Ratio1.26 Quick Ratio1.13 Sales & Book Value Annual Sales$36.19 million Price / Sales2.04 Cash FlowN/A Price / Cash FlowN/A Book Value$0.35 per share Price / Book7.43Miscellaneous Outstanding Shares28,359,000Free FloatN/AMarket Cap$73.73 million OptionableNot Optionable Beta1.02 10 Stocks Set to Soar in Spring 2025Enter your email address and we'll send you MarketBeat's list of ten stocks that are set to soar in Spring 2025, despite the threat of tariffs and other economic uncertainty. These ten stocks are incredibly resilient and are likely to thrive in any economic environment.Get This Free Report This page (NASDAQ:BFRA) was last updated on 5/28/2025 by MarketBeat.com Staff From Our PartnersJuly 2025 Rule Change to Impact Retirement InvestorsThere's a massive change from a new rule going into effect this July. And it's one the Big Banks are alread...Premier Gold Co | SponsoredF1 Engineering Powers This Electric Marine MotorThe future of marine propulsion has arrived - powered by F-1 grade engineering. In collaboration with McLar...The Tomorrow Investor | SponsoredBanks aren’t ready for this altcoin—are you?While everyone's distracted by Bitcoin's moves, a stealth revolution is underway. One altcoin is quietly po...Crypto 101 Media | SponsoredTrump Predicts Dollar DownfallREAD THIS VERY CAREFULLY: If you have $100,000 or more saved for retirement, this may make you VERY angry... ...Augusta Precious Metals | SponsoredAI Meltdown Imminent: Dump These Stocks Now!If you have any money in the markets, especially in AI stocks… Please click here to see Elon Musk’s new inv...Paradigm Press | SponsoredWhite House to reset Social Security?Elon Musk's parting DOGE gift looks set to shock America... A single announcement by July 22nd could soon b...Altimetry | SponsoredMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | Sponsored“You all just got a lot richer”Trump Knows What He’s Doing. When the president says he’s going to let RFK “go wild” … and Big Pharma crash...Brownstone Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Biofrontera AG Please log in to your account or sign up in order to add this asset to your watchlist. Share Biofrontera With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.